NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 365 filers reported holding NEKTAR THERAPEUTICS in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,172 | -60.7% | 5,324 | -62.1% | 0.00% | – |
| Q2 2023 | $8,074 | +1760.4% | 14,043 | -97.7% | 0.00% | -100.0% |
| Q1 2023 | $434 | -66.7% | 617,626 | +7.1% | 0.00% | -50.0% |
| Q4 2022 | $1,304 | -99.9% | 576,888 | +1.2% | 0.00% | -33.3% |
| Q3 2022 | $1,823,000 | -13.3% | 569,839 | +3.0% | 0.00% | 0.0% |
| Q2 2022 | $2,102,000 | -11.7% | 553,249 | +25.2% | 0.00% | 0.0% |
| Q1 2022 | $2,381,000 | -59.3% | 441,771 | +2.1% | 0.00% | -57.1% |
| Q4 2021 | $5,846,000 | -31.9% | 432,681 | -9.5% | 0.01% | -41.7% |
| Q3 2021 | $8,585,000 | +1.5% | 477,995 | -3.1% | 0.01% | +9.1% |
| Q2 2021 | $8,461,000 | -15.1% | 493,076 | -1.1% | 0.01% | -21.4% |
| Q1 2021 | $9,968,000 | +17.9% | 498,425 | +0.2% | 0.01% | +16.7% |
| Q4 2020 | $8,458,000 | +6.6% | 497,517 | +4.0% | 0.01% | 0.0% |
| Q3 2020 | $7,935,000 | -30.0% | 478,285 | -2.3% | 0.01% | -36.8% |
| Q2 2020 | $11,336,000 | +34.8% | 489,473 | +3.9% | 0.02% | +5.6% |
| Q1 2020 | $8,408,000 | -11.1% | 471,035 | +7.5% | 0.02% | +12.5% |
| Q4 2019 | $9,457,000 | +34.2% | 438,109 | +13.2% | 0.02% | +23.1% |
| Q3 2019 | $7,047,000 | -41.9% | 386,890 | +13.4% | 0.01% | -43.5% |
| Q2 2019 | $12,138,000 | -5.8% | 341,149 | -11.0% | 0.02% | -8.0% |
| Q1 2019 | $12,884,000 | -1.5% | 383,451 | -3.6% | 0.02% | -10.7% |
| Q4 2018 | $13,077,000 | -41.5% | 397,849 | +8.4% | 0.03% | -34.9% |
| Q3 2018 | $22,367,000 | +25.0% | 366,917 | +0.1% | 0.04% | +19.4% |
| Q2 2018 | $17,895,000 | -43.2% | 366,474 | +23.7% | 0.04% | -45.5% |
| Q1 2018 | $31,493,000 | +42.7% | 296,380 | -19.8% | 0.07% | +46.7% |
| Q4 2017 | $22,071,000 | +189.8% | 369,568 | +16.5% | 0.04% | +164.7% |
| Q3 2017 | $7,615,000 | +26.1% | 317,292 | +2.7% | 0.02% | +21.4% |
| Q2 2017 | $6,039,000 | -16.0% | 308,897 | +0.8% | 0.01% | -17.6% |
| Q1 2017 | $7,192,000 | +165.9% | 306,422 | +39.0% | 0.02% | +142.9% |
| Q4 2016 | $2,705,000 | -20.2% | 220,422 | +11.8% | 0.01% | -22.2% |
| Q3 2016 | $3,388,000 | +27.9% | 197,204 | +5.9% | 0.01% | +12.5% |
| Q2 2016 | $2,649,000 | +5.1% | 186,170 | +1.6% | 0.01% | 0.0% |
| Q1 2016 | $2,520,000 | -16.7% | 183,254 | +2.1% | 0.01% | -20.0% |
| Q4 2015 | $3,024,000 | +63.7% | 179,459 | +6.5% | 0.01% | +66.7% |
| Q3 2015 | $1,847,000 | -10.3% | 168,559 | +2.4% | 0.01% | -14.3% |
| Q2 2015 | $2,059,000 | +12.0% | 164,576 | -1.6% | 0.01% | +40.0% |
| Q1 2015 | $1,839,000 | -23.2% | 167,206 | +8.3% | 0.01% | -28.6% |
| Q4 2014 | $2,394,000 | +28.9% | 154,451 | +0.4% | 0.01% | +16.7% |
| Q3 2014 | $1,857,000 | -6.3% | 153,870 | -0.5% | 0.01% | 0.0% |
| Q2 2014 | $1,982,000 | +11.5% | 154,580 | +5.4% | 0.01% | +20.0% |
| Q1 2014 | $1,778,000 | +5.5% | 146,677 | -1.2% | 0.01% | 0.0% |
| Q4 2013 | $1,685,000 | +5.8% | 148,487 | -2.6% | 0.01% | 0.0% |
| Q3 2013 | $1,593,000 | -10.2% | 152,447 | -0.7% | 0.01% | -16.7% |
| Q2 2013 | $1,773,000 | – | 153,522 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |